PE20230384A1 - Anticuerpos cd163 o proteinas de union - Google Patents

Anticuerpos cd163 o proteinas de union

Info

Publication number
PE20230384A1
PE20230384A1 PE2022001329A PE2022001329A PE20230384A1 PE 20230384 A1 PE20230384 A1 PE 20230384A1 PE 2022001329 A PE2022001329 A PE 2022001329A PE 2022001329 A PE2022001329 A PE 2022001329A PE 20230384 A1 PE20230384 A1 PE 20230384A1
Authority
PE
Peru
Prior art keywords
antibody
porcine
pigs
ability
antigen binding
Prior art date
Application number
PE2022001329A
Other languages
English (en)
Spanish (es)
Inventor
Charles Owen
Hafid Abdelaali Benchaoui
Christine Tait-Burkard
Original Assignee
Eco Animal Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eco Animal Health Ltd filed Critical Eco Animal Health Ltd
Publication of PE20230384A1 publication Critical patent/PE20230384A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2022001329A 2019-12-24 2020-12-24 Anticuerpos cd163 o proteinas de union PE20230384A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1919294.7A GB201919294D0 (en) 2019-12-24 2019-12-24 Antibodies or binding proteins
PCT/GB2020/053370 WO2021130502A1 (en) 2019-12-24 2020-12-24 Cd163 antibodies or binding proteins

Publications (1)

Publication Number Publication Date
PE20230384A1 true PE20230384A1 (es) 2023-03-06

Family

ID=69322779

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001329A PE20230384A1 (es) 2019-12-24 2020-12-24 Anticuerpos cd163 o proteinas de union

Country Status (13)

Country Link
US (1) US20230203185A1 (https=)
EP (1) EP4081542A1 (https=)
JP (1) JP7702952B2 (https=)
KR (1) KR20220119147A (https=)
CN (1) CN121873247A (https=)
BR (1) BR112022012362A2 (https=)
CL (1) CL2022001706A1 (https=)
CO (1) CO2022010294A2 (https=)
DO (2) DOP2022000136A (https=)
GB (1) GB201919294D0 (https=)
MX (1) MX2022007957A (https=)
PE (1) PE20230384A1 (https=)
WO (1) WO2021130502A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR129879A1 (es) * 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
GB202214979D0 (en) * 2022-10-11 2022-11-23 Eco Animal Health Ltd Binding protein
WO2024156888A1 (en) * 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119569865B (zh) * 2024-12-20 2025-10-10 西北农林科技大学 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3331355T3 (fi) * 2015-08-06 2024-06-17 Univ Missouri Sikojen lisääntymishäiriö- ja keuhkotulehdusoireyhtymävirukselle (PRRSV) resistentti sika ja soluja, joilla on muokattuja CD163-geenejä
US11160260B2 (en) * 2018-04-17 2021-11-02 The Curators Of The University Of Missouri Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)

Also Published As

Publication number Publication date
US20230203185A1 (en) 2023-06-29
JP2023508674A (ja) 2023-03-03
CA3162664A1 (en) 2021-07-01
JP7702952B2 (ja) 2025-07-04
EP4081542A1 (en) 2022-11-02
DOP2022000136A (es) 2022-11-30
DOP2025000290A (es) 2026-02-26
CL2022001706A1 (es) 2023-05-26
KR20220119147A (ko) 2022-08-26
BR112022012362A2 (pt) 2022-09-06
GB201919294D0 (en) 2020-02-05
CO2022010294A2 (es) 2022-10-31
MX2022007957A (es) 2022-10-07
WO2021130502A1 (en) 2021-07-01
CN121873247A (zh) 2026-04-17
CN115151569A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
PE20230384A1 (es) Anticuerpos cd163 o proteinas de union
RU2462475C2 (ru) Антитела против вируса гепатита с
AR110755A1 (es) Anticuerpos dirigidos a hueso
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
CL2023001888A1 (es) Anticuerpos multiespecíficos con especificidad para il-4r e il-31.
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
JP2019505564A5 (https=)
AR075504A1 (es) Moleculas de anticuerpos que tienen especificidad para el ox40 humano
PE20220763A1 (es) Materiales y metodos para modular la inmunidad mediada por celulas t
AR084141A1 (es) Anticuerpos neutralizadores anti-ccl20
AR075047A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit.
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
PH12022552520A1 (en) Antibodies binding siglec15 and uses thereof
PE20232050A1 (es) Anticuerpos anti-cd19 y estructuras car-t
AR125488A1 (es) Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas
FI4031569T3 (fi) Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät
BR112022004603A2 (pt) Anticorpo anti-cd371 ou um fragmento de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico, vetor de expressão, célula hospedeira, métodos e kit
ZA202408388B (en) Antibodies targeting sirp-alpha and uses thereof
PE20240589A1 (es) ANTICUERPOS CD1a Y SU USO
WO2022159839A8 (en) Monoclonal antibodies against coronaviruses and uses thereof
AR116937A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
MX2021014882A (es) Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.